Grifols - GRFS Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GRFS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRFS, but not buy additional shares or sell existing shares.
View GRFS analyst ratings or view top-rated stocks.

6 analysts have issued 12 month price targets for Grifols' shares. Their GRFS share price forecasts range from $11.00 to $20.30. On average, they anticipate the company's share price to reach $15.77 in the next year. This suggests a possible upside of 77.0% from the stock's current price.
View analysts price targets for GRFS or view top-rated stocks among Wall Street analysts.

Grifols' stock was trading at $11.23 at the beginning of 2022. Since then, GRFS shares have decreased by 20.7% and is now trading at $8.91.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our GRFS earnings forecast.

Grifols, S.A. (NASDAQ:GRFS) announced its earnings results on Tuesday, May, 4th. The biotechnology company reported $0.21 earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by $0.01. The biotechnology company earned $1.43 billion during the quarter.

Grifols shares split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were payable to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

205 employees have rated Grifols Chief Executive Officer Raimon Grifols and Victor Grifols Deu on Glassdoor.com. Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Grifols investors own include Gilead Sciences (GILD), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Abbott Laboratories (ABT), Alibaba Group (BABA), Johnson & Johnson (JNJ), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR).

Grifols trades on the NASDAQ under the ticker symbol "GRFS."

Grifols' stock is owned by a number of institutional and retail investors. Top institutional investors include Pictet Asset Management SA (0.78%), SG Americas Securities LLC (0.15%), Henry James International Management Inc. (0.04%), Envestnet Asset Management Inc. (0.02%), Veriti Management LLC (0.02%) and Cardinal Capital Management (0.01%).

Shares of GRFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GRFS stock can currently be purchased for approximately $8.91.

Grifols (NASDAQ:GRFS) has a market capitalization of $6.13 billion and generates $5.84 billion in revenue each year. The biotechnology company earns $223.28 million in net income (profit) each year or $1.14 on an earnings per share basis.

The company employs 23,234 workers across the globe.

Grifols was founded in 1909.

Grifols' mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The official website for the company is www.grifols.com. The biotechnology company can be reached via phone at (493) 571-2200, via email at inversores@grifols.com, or via fax at 34-93-571-0267.